Remarkably, this metabolic reprogramming, which occurs regardless of specific CD38-handling strategy (genetic or drug-induced), makes MM cells more vulnerable to NAD+-depleting agents with massive levels of cell death. This evidence concerns the gene CD38 and Miyoshi myopathy.